$GOVX Q4 '24 Earnings Results & Recap
GeoVax reported Q4 2024 revenues of approximately $4 million (vs. the $2.97M estimate) and a loss of roughly $25 million; the outlook is mixed, with a large BARDA award for the COVID-19 vaccine but uncertainty surrounding timelines for clinical trials of its MPOXX and Gideptin candidates.